Imugene (ASX:IMU) presents CHECKvacc data on TNBC at the 2022 San Antonio Breast Cancer Symposium - Kalkine Media

Follow us on Google News:
 Imugene (ASX:IMU) presents CHECKvacc data on TNBC at the 2022 San Antonio Breast Cancer Symposium
Image source: © Wanton | Megapixl.com


  • Imugene has presented data from Phase I CHECKVacc trial on TNBC patients at a symposium in Texas, USA.
  • Data from the trial implied safety and tolerance of CF33-hNIS-antiPD-L1 in patients with metastatic TNBC.

Imugene Limited (ASX: IMU) has presented first and new data from Phase I CHECKVacc trial on patients having triple negative breast cancer (TNBC). The ASX-listed clinical stage immuno-oncology firm presented the data as a poster presentation at the 2022 San Antonio Breast Cancer Symposium (SABC 2022) in San Antonio. The symposium was held on 9 December 2022 AEDT.

© 2022 Kalkine Media®, Data and image source: Company update

Data from the trial implied that CF33-hNIS-antiPD-L1 administered by intratumoral injection in patients with metastatic TNBC is safe and well tolerated at the tested dose levels. Below are some focal points of the results:

  1. The study enrolled six patients who received at least one dose of CHECKvacc injection at dose level 1 (1 x 10^5 pfu) or dose level 2 (3 x 10^5 pfu).
  2. There were no dose-limiting toxicities and no adverse events related to treatment. However, injection site discoloration was observed in one patient.
  3. 99mTc SPECT imaging for virus tracking from virus induced replication of the human sodium iodide (hNIS) transgene demonstrated improvement in 4/6 (67%) patients in the first two dose levels. Improvement was higher in patients with nodal disease injection than dermal metastasis.
  4. SPECT imaging of patient COH-004 (DL-2) on C1D8 demonstrated substantial improvement of the injected lymph node.
  5. Baseline and on-treatment tumor biopsies of patient COH-004 using spatial immune profiling showed a surge in PD-L1 positive cells following treatment with CHECKVacc. It demonstrated immune activation and tumor microenvironment changes in association with response to therapy.

Read: Imugene (ASX:IMU) doses first patient in VAXINIA intratumoral cohort-2

Overall, data from the trial provide for further evaluation of CHECKVacc in TNBC.

At the time of writing this article, share price of IMU was AU$0.180 apiece.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK